Amylgen is participating to a French Biotech Tour In Japan with UbiFrance
25th January 2013
Amylgen has developed a unique and proprietary know-how on rodent models of Alzheimerís disease and other CNS pathologies (schizophrenia, major depression, hypoxia, amnesia, Parkinsonís disease). As a CRO, Amylgen proposes its services for the rapid and accurate evaluation of compounds at a very early stage of development, bringing a first and highly valuable POC in vivo.
Amylgen will be part of the 7 French companies participating to the Biotech Tour organized by UbiFrance in Japan from January 28th to February 2nd. This Biotech Tour include the participation to Bio Asia and several meetings in Tokyo, Tsukuba, Osaka, Kobe and Nagoya, aiming at discussing potential partnership with local companies.
Interested in this company? Send enquiry